Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials

•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism. Current pharmacological treatment for alcoh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug and alcohol dependence 2019-12, Vol.205, p.107631-107631, Article 107631
Hauptverfasser: Oon-arom, Awirut, Likhitsathain, Surinporn, Srisurapanont, Manit
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107631
container_issue
container_start_page 107631
container_title Drug and alcohol dependence
container_volume 205
creator Oon-arom, Awirut
Likhitsathain, Surinporn
Srisurapanont, Manit
description •Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism. Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism. This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models. This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events. Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.
doi_str_mv 10.1016/j.drugalcdep.2019.107631
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2311925578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871619304089</els_id><sourcerecordid>2330764864</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</originalsourceid><addsrcrecordid>eNqFkUGLFDEQhYMoOK7-h4AXLz0m0-mk421ddlVY8KLnUFOp1gzpzphkVtqLf92MIwherEtB8b1XVD3GuBRbKaR-fdj6fPoCET0dtzshbRsb3ctHbCNHYzshlH7MNqI3uhuN1E_Zs1IOopW2YsN-3k5TQMCVw-I5INKxwj7EUFeeJv4AmZaAMSzEp5R525O-phjK_IZf87KWSjPUgDzTQ6Dvv01mqtDBAnEtoZxNcpumOfwg32Faak4xkuc1B4jlOXsytUYv_vQr9vnu9tPN--7-47sPN9f3HfbG1s4TaBRymAYatPY9jDjslfUgDSkxeqWRpEJrJ6VIml0vjTTgzd4q1Q9S9Ffs1cX3mNO3E5Xq5lCQYoSF0qm4ppB2NwxmbOjLf9BDOuV2z5nq23PVqFWjxguFOZWSaXLHHGbIq5PCnZNxB_c3GXdOxl2SadK3Fym1g9vbsisYaEHyIRNW51P4v8kvR3Od3A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2330764864</pqid></control><display><type>article</type><title>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</title><source>Elsevier ScienceDirect Journals Complete</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><creator>Oon-arom, Awirut ; Likhitsathain, Surinporn ; Srisurapanont, Manit</creator><creatorcontrib>Oon-arom, Awirut ; Likhitsathain, Surinporn ; Srisurapanont, Manit</creatorcontrib><description>•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism. Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism. This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models. This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events. Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2019.107631</identifier><language>eng</language><publisher>Lausanne: Elsevier B.V</publisher><subject>Acceptability ; Alcohol ; Alcohol use ; Alcoholic beverages ; Alcoholism ; Alcohols ; Clinical research ; Clinical trials ; Critical incidents ; Dependence ; Drinking ; Drinking behavior ; Dropping out ; Drug abuse ; Drug therapy ; Drugs ; Efficacy ; Heavy drinkers ; Meta-analysis ; Quality assessment ; Randomization ; Risk assessment ; Risk factors ; School dropout programs ; School dropouts ; Statistical analysis ; Substance abuse treatment ; Systematic review ; Therapy ; Treatment methods ; Varenicline</subject><ispartof>Drug and alcohol dependence, 2019-12, Vol.205, p.107631-107631, Article 107631</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright Elsevier Science Ltd. Dec 1, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</citedby><cites>FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drugalcdep.2019.107631$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids></links><search><creatorcontrib>Oon-arom, Awirut</creatorcontrib><creatorcontrib>Likhitsathain, Surinporn</creatorcontrib><creatorcontrib>Srisurapanont, Manit</creatorcontrib><title>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</title><title>Drug and alcohol dependence</title><description>•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism. Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism. This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models. This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events. Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.</description><subject>Acceptability</subject><subject>Alcohol</subject><subject>Alcohol use</subject><subject>Alcoholic beverages</subject><subject>Alcoholism</subject><subject>Alcohols</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Critical incidents</subject><subject>Dependence</subject><subject>Drinking</subject><subject>Drinking behavior</subject><subject>Dropping out</subject><subject>Drug abuse</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Efficacy</subject><subject>Heavy drinkers</subject><subject>Meta-analysis</subject><subject>Quality assessment</subject><subject>Randomization</subject><subject>Risk assessment</subject><subject>Risk factors</subject><subject>School dropout programs</subject><subject>School dropouts</subject><subject>Statistical analysis</subject><subject>Substance abuse treatment</subject><subject>Systematic review</subject><subject>Therapy</subject><subject>Treatment methods</subject><subject>Varenicline</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqFkUGLFDEQhYMoOK7-h4AXLz0m0-mk421ddlVY8KLnUFOp1gzpzphkVtqLf92MIwherEtB8b1XVD3GuBRbKaR-fdj6fPoCET0dtzshbRsb3ctHbCNHYzshlH7MNqI3uhuN1E_Zs1IOopW2YsN-3k5TQMCVw-I5INKxwj7EUFeeJv4AmZaAMSzEp5R525O-phjK_IZf87KWSjPUgDzTQ6Dvv01mqtDBAnEtoZxNcpumOfwg32Faak4xkuc1B4jlOXsytUYv_vQr9vnu9tPN--7-47sPN9f3HfbG1s4TaBRymAYatPY9jDjslfUgDSkxeqWRpEJrJ6VIml0vjTTgzd4q1Q9S9Ffs1cX3mNO3E5Xq5lCQYoSF0qm4ppB2NwxmbOjLf9BDOuV2z5nq23PVqFWjxguFOZWSaXLHHGbIq5PCnZNxB_c3GXdOxl2SadK3Fym1g9vbsisYaEHyIRNW51P4v8kvR3Od3A</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Oon-arom, Awirut</creator><creator>Likhitsathain, Surinporn</creator><creator>Srisurapanont, Manit</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20191201</creationdate><title>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</title><author>Oon-arom, Awirut ; Likhitsathain, Surinporn ; Srisurapanont, Manit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-dea6c015f5e566d3a8c5b49da17e408d46ce14c99f44e17231717ad7b94435103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acceptability</topic><topic>Alcohol</topic><topic>Alcohol use</topic><topic>Alcoholic beverages</topic><topic>Alcoholism</topic><topic>Alcohols</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Critical incidents</topic><topic>Dependence</topic><topic>Drinking</topic><topic>Drinking behavior</topic><topic>Dropping out</topic><topic>Drug abuse</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Efficacy</topic><topic>Heavy drinkers</topic><topic>Meta-analysis</topic><topic>Quality assessment</topic><topic>Randomization</topic><topic>Risk assessment</topic><topic>Risk factors</topic><topic>School dropout programs</topic><topic>School dropouts</topic><topic>Statistical analysis</topic><topic>Substance abuse treatment</topic><topic>Systematic review</topic><topic>Therapy</topic><topic>Treatment methods</topic><topic>Varenicline</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oon-arom, Awirut</creatorcontrib><creatorcontrib>Likhitsathain, Surinporn</creatorcontrib><creatorcontrib>Srisurapanont, Manit</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oon-arom, Awirut</au><au>Likhitsathain, Surinporn</au><au>Srisurapanont, Manit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials</atitle><jtitle>Drug and alcohol dependence</jtitle><date>2019-12-01</date><risdate>2019</risdate><volume>205</volume><spage>107631</spage><epage>107631</epage><pages>107631-107631</pages><artnum>107631</artnum><issn>0376-8716</issn><eissn>1879-0046</eissn><abstract>•Current pharmacological treatment for alcoholism remains unsatisfactory.•Varenicline may have a medium effect size in decreasing alcohol consumption.•Varenicline is well tolerable and accepted.•Varenicline may be an option for the treatment of alcoholism. Current pharmacological treatment for alcoholism remains unsatisfactory. While there have been several clinical trials investigating the efficacy and safety of the therapeutic use of varenicline in alcoholism, no definitive review of this topic has been carried out. This systematic review aimed to determine the efficacy and acceptability of the use of varenicline in treating alcoholism. This systematic review included double-blinded, randomized, placebo-controlled trials reporting heavy drinking days, amount of alcohol consumption, overall dropouts, or dropouts due to adverse events. We searched PubMed, Scopus, Web of Science, ClinicalTrials.gov, and the Cochrane Library in January 2019. We independently selected the trials and assessed the quality of included studies. We calculated standardized mean differences on heavy drinking days and the amount of alcohol consumption. We calculated the relative risks for dropout rate. All data were pooled using random-effects models. This systematic review included nine double-blind, randomized, placebo-controlled trials (N = 585). The study duration ranged from 4 to 13 weeks. Varenicline therapy was not superior to placebo in decreasing heavy drinking days but significantly superior to placebo in decreasing alcohol consumption. There were no statistically significant differences between groups on dropout rates due to any reason or due to adverse events. Varenicline therapy is effective in decreasing alcohol consumption over a period of time. It may be an option for decreasing heavy drinking days in patients with alcoholism. It is a well-accepted medication for alcoholism. More studies are needed to determine if varenicline is effective in decreasing heavy drinking.</abstract><cop>Lausanne</cop><pub>Elsevier B.V</pub><doi>10.1016/j.drugalcdep.2019.107631</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0376-8716
ispartof Drug and alcohol dependence, 2019-12, Vol.205, p.107631-107631, Article 107631
issn 0376-8716
1879-0046
language eng
recordid cdi_proquest_miscellaneous_2311925578
source Elsevier ScienceDirect Journals Complete; Applied Social Sciences Index & Abstracts (ASSIA)
subjects Acceptability
Alcohol
Alcohol use
Alcoholic beverages
Alcoholism
Alcohols
Clinical research
Clinical trials
Critical incidents
Dependence
Drinking
Drinking behavior
Dropping out
Drug abuse
Drug therapy
Drugs
Efficacy
Heavy drinkers
Meta-analysis
Quality assessment
Randomization
Risk assessment
Risk factors
School dropout programs
School dropouts
Statistical analysis
Substance abuse treatment
Systematic review
Therapy
Treatment methods
Varenicline
title Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A03%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20acceptability%20of%20varenicline%20for%20alcoholism:%20A%20systematic%20review%20and%20meta-analysis%20of%20randomized-controlled%20trials&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Oon-arom,%20Awirut&rft.date=2019-12-01&rft.volume=205&rft.spage=107631&rft.epage=107631&rft.pages=107631-107631&rft.artnum=107631&rft.issn=0376-8716&rft.eissn=1879-0046&rft_id=info:doi/10.1016/j.drugalcdep.2019.107631&rft_dat=%3Cproquest_cross%3E2330764864%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2330764864&rft_id=info:pmid/&rft_els_id=S0376871619304089&rfr_iscdi=true